SpringWorks Shares Drop 39% After Drug Study Data, Wedbush Price Target Cut
marketwatch.com
news
2022-05-27 18:28:00

By Josh Beckerman SpringWorks Therapeutics Inc. shares were down 39% to $18.67 Friday after the company reported drug study data and Wedbush lowered its price target to $50 a share from $110. SpringWorks reported initial clinical data from the Phase 1/2 study evaluating nirogacestat in combination with GSK PLC's Blenrep in patients with relapsed or refractory multiple myeloma. In addition, SpringWorks highlighted long-term follow-up data from a Phase 2 study evaluating nirogacestat in patients with progressing desmoid tumors.
